<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Therapies</td>
<td></td>
<td>See article, p. 1422</td>
</tr>
<tr>
<td>1312</td>
<td>New Data Supporting Modified RECIST (mRECIST) for Hepatocellular</td>
<td>Riccardo Lencioni</td>
<td>New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma.</td>
</tr>
<tr>
<td></td>
<td>Carcinoma</td>
<td></td>
<td>See article, p. 1503</td>
</tr>
<tr>
<td>1315</td>
<td>Is the European Pediatric Medicine Regulation Working for Children</td>
<td>Gilles Vassal, Birgit Geoerger, and Bruce Morland</td>
<td>Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer.</td>
</tr>
<tr>
<td></td>
<td>and Adolescents with Cancer?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1326</td>
<td>Borrowing Information across Subgroups in Phase II Trials: Is It</td>
<td>Boris Freidlin and Edward L. Korn</td>
<td>Borrowing Information across Subgroups in Phase II Trials: Is It Useful?</td>
</tr>
<tr>
<td></td>
<td>Useful?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1335</td>
<td>Enzalutamide: A Novel Antiandrogen for Patients with Castrate-</td>
<td>Jean Hoffman-Censits and Wm. Kevin Kelly</td>
<td>Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer.</td>
</tr>
<tr>
<td></td>
<td>Resistant Prostate Cancer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**HUMAN CANCER BIOLOGY**

- **Murine Microenvironment Metaproteomes Associate with Human Cancer Etiology and Intrinsic Subtypes**
  - David H. Nguyen, Erik Fredlund, Wei Zhao, Charles M. Perou, Allan Balmain, Jian-Hua Mao, and Mary Helen Barcellos-Hoff
- **PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction**
  - Kaoru Abiko, Masaki Mandai, Junzo Hamanishi, Yumiko Yoshioka, Noriomi Matsumura, Tsukasa Baba, Ken Yamaguchi, Ryusuke Murakami, Ayaka Yamamoto, Budiman Khanna, Kenzo Kosaka, and Ikao Konishi
- **Rab25 Regulates Invasion and Metastasis in Head and Neck Cancer**
  - Panomvat Amorphimoltham, Kamil Recheke, Jamie Thompson, Andrius Masedunskas, Kantima Leelahavannichkul, Vymesh Patel, Alfredo Molinolo, J. Silvio Gutkind, and Roberto Weigert
- **MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer**
  - San-Jian Yu, Jing-Ying Hu, Xia-Ying Kuang, Jian-Min Lao, Yi-Feng Hou, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Hou-Yan Song, and Zhi-Ming Shao
- **HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification**
  - Jianghua Zheng, Jinglong Wang, Xueqing Sun, Mingang Hao, Tao Ding, Dan Xiong, Xiumin Wang, Yu Zhu, Gang Xiao, Guangsun Cheng, Meizhong Zhao, Jian Zhang, and Jianhua Wang
- **Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer**
Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia
Seiichiro Katagiri, Tetsuzo Tauchi, Seiichi Okabe, Yosuke Minami, Shinya Kimura, Taira Maekawa, Tomoki Naoe, and Kazuma Ohyashiki

See commentary, p. 1309

Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition
Ying Zhang, Kaitlyn E. Farenholtz, Yanzhi Yang, Fadila Guessous, Charles G. diPierro, Valerie S. CalVERT, Jianghong Deng, David Schiff, Wenzun Xin, Jae K. Lee, Benjamin Purrow, James Christensen, Emmanuel Petricoin, and Roger Abounader

Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
Lorenz Bastian, Jana Hof, Madlen Pfau, Iduna Fichtner, Cornelia Eckert, Günter Henze, Javier Prada, Arend von Stackelberg, Karl Seeger, and Shabnam Shalapour

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Eric I. Zimmerman, ShuIying Hu, Justin L. Roberts, Alice A. Gibson, Shelley J. OrwicK, Lie Li, Alex Sparreboom, and Sharyn D. Baker

Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells
Teun Guichelaar, Maarten E. Emmlot, Henk Rozemuller, Bianka Martini, Richard W.J. Groen, Gert Storm, Henk M. Lokhorst, Anton C. Martens, and Tuna Mutis

Effective Anti-Neu–Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells
Eric D. Mortenson, SaeGwang Park, Zhujun Jiang, Shengdian Wang, and Yang-Xin Fu

18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors
Anish Thomas, Esther Mena, Karen Kurzziel, David Venzon, Sean Khozin, Arlene W. Berman, Peter Choyke, Eva Szabo, Arun Rajan, and Giuseppe Giaccone

Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma

Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
Beom Kyung Kim, Seung Up Kim, Myeong-Jin Kim, Kyung Ah Kim, Do Young Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, and Chae Yoon Chon

Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Anne F. Schott, Melissa D. Landis, Gabriela Dontu, Kent A. Griffith, Rachel M. Layman, Ian Krop, Lacey A. Paskett, Helen Wong, Lacey E. Dobrolecki, Michael T. Lewis, Amber M. Froehlich, Jaya Paranilam, Daniel F. Hayes, Max S. Wicha, and Jenny C. Chang

Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells
Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization
Ruben Niesvizky, Tomer M. Mark, Maureen Ward, David S. Jayabalal, Roger N. Pearce, Megan Manco, Jessica Stern, Paul J. Christos, Lena Mathews, Tsiopoth B. Shore, Faiza Zafar, Karen Pekle, Zhaoying Xiang, Scott Ely, Donna Skerret, Selina Chen-Kiang, Morton Coleman, and Maureen E. Lane

Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer
Firas L. T. Al-Ubaidi, Niklas Schultz, Olga Loseva, Lars Egevad, Torvald Granfors, and Thomas Hellday

Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Maria J.A. Ribeiro, Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri, and Johann C. Brandes

Phase I Study of GRN1005 in Recurrent Malignant Glioma
Jan Drappatz, Andrew Brenner, Eric T. Wong, April Eichler, David Schiff, Morris D. Groves, Tom Mikkelson, Steve Rosenfeld, John Sarantopoulos, Christina A. Meyers, Robert M. Fielding, Kelly Elian, Xiaolin Wang, Betty Lawrence, Mona Shing, Stephen Kelsey, Jean Paul Castaigne, and Patrick Y. Wen

Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Christine E. Horak, Lajos Pusztai, Guan Xing, Ovidiu C. Trifan, Cristina Saura, Ling-Ming Tseng, Stephen Chan, Rosanne Welcher, and David Liu

Establishment and Validation of Circulating Tumor Cell-Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients
Antonio Giordano, Brian L. Egleston, David Hajage, Joseph Bland, Gabriel N. Hortobagyi, James M. Reuben, Jean-Yves Pierga, Massimo Cristofanilli, and Francois-Clement Bidal

CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC
Rathi N. Pillai, Seth A. Brodie, Gabriel L. Sica, You Shaojin, Ge Li, Dana C. Nickleach, Liu Yuan, Vijay A. Varma, Dacian Bonta, James G. Herman, Malcolm V. Brock, Maria J.A. Ribeiro, Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri, and Johann C. Brandes

A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer

Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy

A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Hao Tang, Guanghua Xiao, Carmen Behrens, Joan Schiller, Jeffrey Allen, Chi-Wan Chow, Milind Suraoar, Alejandro Corvalan, Jianhua Mao, Michael A. White, Ignacio I. Wistuba, John D. Minna, and Yang Xie

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Hao Tang, Guanghua Xiao, Carmen Behrens, Joan Schiller, Jeffrey Allen, Chi-Wan Chow, Milind Suraoar, Alejandro Corvalan, Jianhua Mao, Michael A. White, Ignacio I. Wistuba, John D. Minna, and Yang Xie
ABOUT THE COVER

The microphotograph shows the induction of apoptosis after combined treatment with bortezomib and the histone deacetylase inhibitor valproic acid in a xenograft mouse model of acute lymphoblastic leukemia (ALL). Human B-cell precursor ALL cells were injected subcutaneously into nonobese diabetic/severe combined immunodeficient mice. Tumor sections after treatments were stained with mAbs against human CD10 (red) indicating leukemia cells, cleaved caspase-3 (green) indicating apoptotic cells, and 4',6-diamidino-2-phenylindole (nuclei, blue). For details, please see the article by Bastian and colleagues on page 1445 of this issue.